Skip to Content

Immunotech Laboratories Inc IMMB

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IMMB is trading at a 755% premium.
Price
$0.00
Fair Value
$3.89
Uncertainty
Extreme
1-Star Price
$4.55
5-Star Price
$1.41
Economic Moat
Srn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMMB is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.01
Bid/Ask
/
Market Cap
$55.07
Volume/Avg
3,025 / 3,013

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Immunotech Laboratories Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction peptide molecule for the specific treatment and preventing of the HIV/AIDS indication.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
4
Website

Valuation

Metric
IMMB
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IMMB
Quick Ratio
0.01
Current Ratio
0.01
Interest Coverage
−51.46
Quick Ratio
No chart available

Profitability

Metric
IMMB
Return on Assets (Normalized)
−9.35%
Return on Equity (Normalized)
−14.49%
Return on Invested Capital (Normalized)
−12.07%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBhhwvlpnRft$586.1 Bil
VRTX
Vertex Pharmaceuticals IncMcqxqbzcGxspchg$113.7 Bil
REGN
Regeneron Pharmaceuticals IncPwkqnnkvwStmwwj$108.2 Bil
MRNA
Moderna IncRtdszsjwSby$50.9 Bil
ARGX
argenx SE ADRRdqfbrjcHqt$22.0 Bil
BNTX
BioNTech SE ADRZvnzwllFkfj$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncScmrpgxzgYdrjgz$18.9 Bil
BMRN
Biomarin Pharmaceutical IncPbvmgfhszVkxbfm$14.6 Bil
INCY
Incyte CorpFqlxqmzgRwkxlj$12.8 Bil
RPRX
Royalty Pharma PLC Class AZmctttxglgMpmdlmg$12.3 Bil

Sponsor Center